Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings (Nasdaq: ASRT) has scheduled the release of its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after market close. The company will host a live webcast earnings conference call at 4:30 p.m. Eastern Time following the results announcement.
Investors can access the webcast through Assertio's investor relations website, with connection recommended 10 minutes prior to start. For telephone participation, participants should dial +1-646-307-1963 with call ID 3278948. A replay will be available approximately two hours after the call on the company's investor website.
Assertio Holdings (NASDAQ: ASRT) has announced inducement grants for its newly-hired Senior Vice President and Chief Commercial Officer, Mary Pietryga. The compensation package, approved by the Company's Board of Directors' Compensation Committee on December 23, 2024, includes 62,500 restricted stock units (RSUs) and 275,000 stock options.
The stock options have an exercise price of $0.846 per share, matching Assertio's common stock closing price on the grant date. Both RSUs and options will vest equally over three years, starting from the first anniversary of the grant date. These grants were made as inducement materials for employment in accordance with NASDAQ Listing Rule 5635(c)(4).
Assertio Holdings (Nasdaq: ASRT) has appointed Mark Reisenauer as an independent director to its Board of Directors, where he will serve on the Compensation Committee. Reisenauer brings over 30 years of experience in the biopharmaceutical industry, particularly in oncology and hematology. His previous role as President of U.S. Commercial at Astellas Pharmaceuticals saw him grow sales to nearly $5 billion while leading Marketing, Sales, Policy and Government Affairs, and Market Access teams.
The appointment aligns with Assertio's strategy to enhance its commercial platform and explore additional labeling, indication, and channel opportunities for existing products while seeking new commercial assets. Reisenauer's experience includes executive positions at Micromet Inc., Abbott Laboratories, Pharmacia , Bristol-Myers Squibb, and Zeneca Pharmaceuticals.
Assertio Holdings (NASDAQ: ASRT) announced results from a clinical trial evaluating Rolvedon® (eflapegrastim-xnst) injection when administered on the same day as chemotherapy for early stage breast cancer patients. The open-label, single-arm study, conducted across 13 US sites, demonstrated that Rolvedon, when given 30 minutes post-chemotherapy, achieved 1.8 days to neutrophil count recovery with a 2% febrile neutropenia rate. Notably, no patients required hospitalization for febrile neutropenia, and no new safety concerns were identified. The results were presented at the San Antonio Breast Cancer Symposium.
Assertio Holdings (NASDAQ: ASRT) announced key leadership changes with the creation of a new Transformation Office. Paul Schwichtenberg, current Chief Commercial Officer and former CFO, has been appointed as Chief Transformation Officer (CTO). In his previous roles, Schwichtenberg implemented efficiency measures, pricing strategies, and debt refinancing that improved profitability and strengthened the company's balance sheet.
Mary Pietryga will assume the role of Chief Commercial Officer effective December 16, 2024. Pietryga joins from Teva Pharmaceuticals, where she served as VP and Head of Global Biosimilar Portfolio. Her experience includes leadership positions at Peregrine Market Access, Pacira Biosciences, and other major pharmaceutical companies.
The Buxton Helmsley Group (BHG), which recently converted its position in Assertio Holdings (NASDAQ: ASRT) to a short interest, has called for a Senate Committee investigation into alleged clinical data fraud at Spectrum Pharmaceuticals, now owned by Assertio. This request follows the resignation of Assertio's Chairman and oncologist board member, announced shortly after BHG's release of a 20-page exposé. The report cites former executives-turned-whistleblowers who claim to possess evidence of clinical data tampering related to the cancer treatment Rolvedon. BHG criticizes Assertio's CEO Brendan O'Grady's dismissal of the allegations and the company's failure to engage with whistleblowers or review their evidence.
Assertio Holdings (NASDAQ: ASRT) reported Q3 2024 financial results with total net product sales of $28.7 million, including $15.0 million from Rolvedon. The company posted a net loss of $2.9 million, or $(0.03) per share. Rolvedon sales remained stable quarter-over-quarter, while Indocin sales decreased to $5.7 million due to generic competition. The company maintained a strong balance sheet with $88.6 million in cash and short-term investments. Gross margin improved to 74% from 71% in Q2, and Adjusted EBITDA increased to $5.3 million from $5.0 million in the previous quarter.
The Buxton Helmsley Group (BHG), which holds a short position in Assertio Holdings (NASDAQ: ASRT), has released evidence supporting allegations of product-related fraud at Spectrum Pharmaceuticals, now owned by Assertio. The evidence includes a memo showing requests to delete adverse event data and audit reports revealing major discrepancies in clinical trial data. BHG has filed a whistleblower complaint with the SEC and calls on Assertio's board to release their full investigation report and documentation of communication with whistleblowers. BHG claims Assertio's recent denial fails to address specific allegations, including alleged 'hush money' offers to whistleblowers.
Assertio Holdings (NASDAQ: ASRT) has issued a response to allegations made by short-seller Alex Parker of Buxton Hemsley Group. CEO Brendan O'Grady strongly refuted claims about Rolvedon's safety and the company's accounting practices, stating they are false and baseless. The company revealed that Parker, who initially positioned himself as an activist investor, attempted to negotiate payment of his legal fees in exchange for dropping his activist activities. After unsuccessful attempts to extract money and a board position, Parker has now shifted to a short-selling position. Assertio is considering legal and regulatory action in response.
Buxton Helmsley Group (BHG) has announced its transition from a long to a short position in Assertio Holdings (ASRT), citing serious concerns over alleged product-related fraud. The investment fund claims to have uncovered evidence from multiple former Spectrum executives-turned-whistleblowers regarding safety issues with Rolvedon, a product acquired through the Spectrum Pharmaceuticals merger. BHG alleges that Assertio's board has failed to properly investigate these concerns, despite reported inquiries from various federal health agencies. The fund suggests the Spectrum acquisition was rushed due to Assertio's flagship product Indocin facing imminent generic competition, potentially defrauding both Assertio and Spectrum stockholders.